WORK EXPERIENCE
2020 – present: Faculty Member of PhD “Network Oncology and Precision Medicine”, Sapienza University of Rome
2018 – present: RTDA Researcher
2019 – 2020: Coordinator of the youth section Italian Association of Medical Oncology (Associazione Italiana di Oncologia Medica AIOM) Lazio
2016 – present: Coordinator and Professor at IMMUNO-ONCOLOGY MASTER II LEVEL, Sapienza, University of Rome
2015 – 2018: PhD research fellow, Sapienza University of Rome
2006 - 2009: Internship - Division of Medical Oncology - Sant’Andrea Hospital, Rome. Director: Prof. P. Marchetti
2005 - 2006: Internship - Division of Molecular Oncology Prof. Gulino, La Sapienza University of Rome
EDUCATION AND TRAINING
2015 - 2018: Ph.D. degree in Experimental Medicine, Sapienza University of Rome
2018: Certificate of Pedagogy and medical teaching, Sapienza, University of Rome
2016: Certificate of Oncofertility course, Sapienza, University of Rome
2010 -2015: Specialty in Medical Oncology, Sapienza University of Rome
2010: Medical License, Registration at the Medical Register of Rome, Nr. 57700.
2009: Medical Doctor degree at Sapienza University of Rome.
WORK ACTIVITIES
Research projects
The research activity is focused on precision/personalized medicine and breast cancer. In particular, on the research of biomarkers able to identify the patient’s metabolism (study of SNPs) in order to avoid unnecessary toxicity and to increase the compliance to treatment. Furthermore it was focused on the research of biomarkers able to identify the patients prone to respond to target therapy. In this regard, I’m the PI of Rome Trial ( NCT04591431)with the aim to demonstrate the possibile efficacy of the agnostic approach. In the last years the research was expanded to immunology, investigating several biomarkers on blood, tissue and microbiome.
The research activity was characterized by the collaboration with several instution such as the Microbiome Unit of Pediatric Hospital Bambino Gesù IRCCS, Istituto Superiore di Sanità, and several Oncological centers (the Rome trial involved 46 oncological centers).
Fields of interest: Personalized medicine, Immunotherapy, Precision immunotherapy, Target therapy, Breast cancer, Agnostic approach
Awards
Awarded the National Scientific Qualification for Associate Professor for the SC 06/D3 in 9/7/2020.
Winner Preceptorship ESMO Immuno-Oncology Congress. 29 September -1 October 2016
Participation in Italian and International research groups and clinical trials as Principal Investigator or Investigator.
2020 – present: Principal Investigator of 2 clinical trials “The Rome trial”; “Observational study to assess the absolute burden of HPV-related head and neck cancers BROADEN study”
2013 – present: Investigator of 6 clinical trials “A phase III randomized double blind placebo controlled study of BMK120 with fulvestrant in post menopausal women with hormone receptor positive HER2 negative locally advanced or metastatic breast cancer”; “KATHERINE trial”; “Immunological evaluation of cancer patients. CE 4181 University of Rome La Sapienza”; “WO40242 Head and Neck carcinoma”; “Javelin BRCA/ATM: Avelumab plus talazopariv in Patients with BRCA or ATM mutant solid tumors”; “NEED trial : nivolumab in Head and Neck patients: a real World Experience CE5618 University of Rome, La Sapienza”.
2020 – present: Elective committee of Hemato-Onco-Dermatology, AOU Policlinico Umberto I, Rome
2018 – 2020: Member of Committee PDTA breast cancer, Lazio
2019 – present: Breast Unit , AOU Policlinico Umberto I, Head and Neck Unit AOU Policlinico Umberto I Rome
2019 – 2020: Coordinator of the youth section Italian Association of Medical Oncology (Associazione Italiana di Oncologia Medica AIOM) Lazio
Editorial activity
International Scientific Board Member of Frontiers in Oncology and Journal of Translational Medicine
Invited presentations
At Italian association of Medical Oncology (AIOM); At American society of Clinical Oncology (ASCO);
International memberships
Member since 2016 of: European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Italian Association of Medical Oncology (Associazione Italiana di Oncologia Medica AIOM)
Grants - Funding track record in the last 5 years
“Microbiome and Immunotherapy : a novel personalized managment for side effects. Sapienza University Research Grant “Avvio alla ricerca” 2016-2017. Duration: 1 year. Principal Investigator: Andrea Botticelli. 2.000€
Rome Trial, from the Histology to target NCT04591431. Principal Investigator: Andrea Botticelli. 2.300.000€
ADDITIONAL INFORMATION
Publications
Scientific Production and Bibliometric Indicators for 2013-2022 period, first publication in 2013.
- Number of publications: 107 in total full papers in international scientific journals.
- Impact factor IF 2020: 565.518
- Average IF 2020/paper: 5.28
- Total number of citations: 1344 (source Scopus)
- Average citations/paper: 12.56
- Hirsch index (H-index): 20 (source Scopus)
- Total number of manuscripts as a first author: 18
- Total number of manuscripts as last author: 4
Complete list of publications can be found at: Scopus Author ID 55651223000: https://www.scopus.com/authid/detail.uri?authorId=55651223000